AC Immune(ACIU) Newsfilter·2024-07-16 11:00Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company specializing in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins [3] - The company has two clinically validated technology platforms, SupraAntigen® and Morphomer®, which support a diversified pipeline of 16 therapeutic and diagnostic programs, with five in Phase 2 clinical trials and one in Phase 3 [3] - AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding through milestone payments and royalties [3] AAIC 2024 Presentations - AC Immune will present three oral presentations at the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, PA, from July 28 to August 1, 2024 [1] - The presentations will cover the discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43-PET tracer, on July 29, 2024 [2] - Another presentation will discuss ACI-24.060, an active immunotherapy that induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies, on July 30, 2024 [2] - The third presentation will introduce morADC (Morphomer®-Antibody Drug Conjugates), a new class of neurodegenerative disease-fighting drugs, on July 31, 2024 [2] Technology Platforms - SupraAntigen® is a registered trademark of AC Immune SA in multiple territories, including AU, EU, CH, GB, JP, RU, SG, and USA [4] - Morphomer® is also a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO, and RU [4]